Hepatic pathobiology of iron overload

Iron Physiology and Pathophysiology in Humans

Volumn , Issue , 2012, Pages 357-383

  Ruddell, Richard G ^a   Ramm, Grant A ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cirrhosis; Fibrosis; Free radical; Heart; Hepatocellular carcinoma; Ischemic heart disease; Liver; Pancreas; Reactive oxygen species

Indexed keywords

EID: 84880581845     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-485-2_18     Document Type: Chapter

References (194)

1. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci. 1998;854:328-35.
2. Videla LA, Fernandez V, Tapia G, Varela P. Oxidative stress-mediated hepatotoxicity of iron and copper: role of kupffer cells. Biometals. 2003;16:103-11.
3. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001;35:297-306.
4. Pietrangelo A. Iron-induced oxidant stress in alcoholic liver fibrogenesis. Alcohol. 2003;30:121-9.
5. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489-92.
6. Sies H. Oxidative stress: from basic research to clinical application. Am J Med. 1991;91:31S-8S.
7. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol. 2002;76:219-28.
8. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology. 1990;11:127-37.
9. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis. 2005;25:433-49.
10. Iancu TC, Shiloh H. Morphologic observations in iron overload: an update. Adv Exp Med Biol. 1994;356:255-65.
11. Kurz T, Terman A, Gustafsson B, Brunk UT. Lysosomes in iron metabolism, ageing and apoptosis. Histochem Cell Biol. 2008;129:389-406.
12. O'Connell MJ, Ward RJ, Baum H, Peters TJ. The role of iron in ferritin-and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J. 1985;229:135-9.
13. Peters TJ, Seymour CA. Acid hydrolase activities and lysosomal integrity in liver biopsies from patients with iron overload. Clin Sci Mol Med. 1976;50:75-8.
14. Seymour CA, Peters TJ. Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes. Br J Haematol. 1978;40:239-53.
15. Hultcrantz R, Ahlberg J, Glaumann H. Isolation of two lysosomal populations from iron-overloaded rat liver with different iron concentration and proteolytic activity. Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;47:55-65.
16. LeSage GD, Kost LJ, Barham SS, LaRusso NF. Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. J Clin Invest. 1986;77:90-7.
17. Bacon BR, O'Neill R, Britton RS. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology. 1993;105(4):1134-40.
18. Bacon BR, O'Neill R, Park CH. Iron-induced peroxidative injury to isolated rat hepatic mitochondria. J Free Radic Biol Med. 1986;2:339-47.
19. Zhao M, Antunes F, Eaton JW, Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem. 2003;270:3778-86.
20. Thomas C, Mackey MM, Diaz AA, Cox DP. Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep. 2009;14:102-8.
21. Pardo Andreu GL, Inada NM, Vercesi AE, Curti C. Uncoupling and oxidative stress in liver mitochondria isolated from rats with acute iron overload. Arch Toxicol. 2009;83:47-53.
22. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34:232-7.
23. Rauen U, Petrat F, Sustmann R, de Groot H. Iron-induced mitochondrial permeability transition in cultured hepatocytes. J Hepatol. 2004;40:607-15.
24. Britton RS, O'Neill R, Bacon BR. Chronic dietary iron overload in rats results in impaired calcium sequestration by hepatic mitochondria and microsomes. Gastroenterology. 1991;101:806-11.
25. Masini A, Ceccarelli D, Trenti T, Corongiu FP, Muscatello U. Perturbation in liver mitochondrial Ca2+ homeostasis in experimental iron overload: a possible factor in cell injury. Biochim Biophys Acta. 1989;1014:133-40.
26. Garcia N, Garcia JJ, Correa F, Chavez E. The permeability transition pore as a pathway for the release of mitochondrial DNA. Life Sci. 2005;76:2873-80.
27. Walter PB, Knutson MD, Paler-Martinez A, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA. 2002;99:2264-9.
28. Pardo Andreu G, Delgado R, Velho J, et al. Mangifera indica L. Extract (vimang) inhibits Fe2+-citrate-induced lipoperoxidation in isolated rat liver mitochondria. Pharmacol Res. 2005;51:427-35.
29. Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev. 2004;28:385-91.
30. Uchida K, Szweda LI, Chae HZ, Stadtman ER. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci USA. 1993;90:8742-6.
31. Tuma DJ. Role of malondialdehyde-acetaldehyde adducts in liver injury. Free Radic Biol Med. 2002;32:303-8.
32. Thiele GM, Worrall S, Tuma DJ, et al. The chemistry and biological effects of malondialdehyde-acetaldehyde adducts. Alcohol Clin Exp Res. 2001;25(5 Suppl ISBRA):218S-24S. doi: 218S .
33. Kharbanda KK, Todero SL, Shubert KA, Sorrell MF, Tuma DJ. Malondialdehyde-acetaldehyde-protein adducts increase secretion of chemokines by rat hepatic stellate cells. Alcohol. 2001;25:123-8.
34. Kharbanda KK, Shubert KA, Wyatt TA, Sorrell MF, Tuma DJ. Effect of malondialdehyde-acetaldehyde-protein adducts on the protein kinase C-dependent secretion of urokinase-type plasminogen activator in hepatic stellate cells. Biochem Pharmacol. 2002;63:553-62.
35. Nair J, Carmichael PL, Fernando RC, et al. Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol Biomarkers Prev. 1998;7:435-40.
36. Hussain SP, Raja K, Amstad PA, et al. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA. 2000;97:12770-5.
37. Henle ES, Linn S. Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide. J Biol Chem. 1997;272:19095-8.
38. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152:159-66.
39. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet. 2009;374:1704-13.
40. Bjornsson E. The natural history of drug-induced liver injury. Semin Liver Dis. 2009;29:357-63.
41. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29:2309-24.
42. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
43. Ramm GA, Crawford DH, Powell LW, et al. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol. 1997;26:584-92.
44. Philippe MA, Ruddell RG, Ramm GA. Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol. 2007;13:4746-54.
45. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669-73.
46. Anderson GJ, Frazer DM. Hepatic iron metabolism. Semin Liver Dis. 2005;25:420-32.
47. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6:24-9.
48. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol. 2001;96:567-9.
49. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294-301.
50. Stal P, Broome U, Scheynius A, Befrits R, Hultcrantz R. Kupffer cell iron overload induces intercellular adhesion molecule-1 expression on hepatocytes in genetic hemochromatosis. Hepatology. 1995;21:1308-16.
51. Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood. 2008;111:4456-62.
52. Zhao M, Laissue JA, Zimmermann A. Hepatocyte apoptosis in hepatic iron overload diseases. Histol Histopathol. 1997;12:367-74.
53. Moerman P, Pauwels P, Vandenberghe K, et al. Neonatal haemochromatosis. Histopathology. 1990;17:345-51.
54. Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest. 1990;86:1991-8.
55. Houglum K, Ramm GA, Crawford DH, et al. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology. 1997;26:605-10.
56. Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Ventura E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest. 1995;95:1824-31.
57. Dai J, Huang C, Wu J, et al. Iron-induced interleukin-6 gene expression: possible mediation through the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. Toxicology. 2004;203:199-209.
58. Hagen K, Eckes K, Melefors O, Hultcrantz R. Iron overload decreases the protective effect of tumour necrosis factor-alpha on rat hepatocytes exposed to oxidative stress. Scand J Gastroenterol. 2002;37:725-31.
59. Hagen K, Zhu C, Melefors O, Hultcrantz R. Susceptibility of cultured rat hepatocytes to oxidative stress by peroxides and iron. The extracellular matrix affects the toxicity of tert-butyl hydroperoxide. Int J Biochem Cell Biol. 1999;31:499-508.
60. Cederbaum AI. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. J Gastroenterol Hepatol. 2006;21 Suppl 3:S22-5.
61. De Domenico I, Ward DM, Nemeth E, et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA. 2005;102:8955-60.
62. She H, Xiong S, Lin M, et al. Iron activates NF-kappaB in kupffer cells. Am J Physiol Gastrointest Liver Physiol. 2002;283:G719-26.
63. Xiong S, She H, Sung CK, Tsukamoto H. Iron-dependent activation of NF-kappaB in kupffer cells: a priming mechanism for alcoholic liver disease. Alcohol. 2003;30:107-13.
64. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol. 1997;272:G1355-1364.
65. Tsukamoto H, Rippe R, Niemela O, Lin M. Roles of oxidative stress in activation of kupffer and Ito cells in liver fibrogenesis. J Gastroenterol Hepatol. 1995;10 Suppl 1:S50-3.
66. Kobune M, Kohgo Y, Kato J, Miyazaki E, Niitsu Y. Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology. 1994;19(6):1468-75.
67. Oudar O, Moreau A, Feldmann G, Scoazec JY. Expression and regulation of intercellular adhesion molecule-1 (ICAM-1) in organotypic cultures of rat liver tissue. J Hepatol. 1998;29:901-9.
68. Selzner N, Selzner M, Odermatt B, et al. ICAM-1 triggers liver regeneration through leukocyte recruitment and kupffer cell-dependent release of TNF-alpha/IL-6 in mice. Gastroenterology. 2003;124:692-700.
69. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38:1188-98.
70. Tsukamoto H, Horne W, Kamimura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995;96:620-30.
71. Takeyama Y, Kamimura S, Kuroiwa A, et al. Role of kupffer cell-derived reactive oxygen intermediates in alcoholic liver disease in rats in vivo. Alcohol Clin Exp Res. 1996;20(9 Suppl):335A-9A.
72. Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood. 2004;103:1509-14.
73. Houglum K, Bedossa P, Chojkier M. TGF-beta and collagen-alpha 1 (I) gene expression are increased in hepatic acinar zone 1 of rats with iron overload. Am J Physiol. 1994;267:G908-13.
74. Solecki R, von Zglinicki T, Muller HM, Clausing P. Iron overload of spleen, liver and kidney as a consequence of hemolytic anaemia. Exp Pathol. 1983;23:227-35.
75. Bridle KR, Crawford DH, Fletcher LM, Smith JL, Powell LW, Ramm GA. Evidence for a sub-morphological inflammatory process in the liver in haemochromatosis. J Hepatol. 2003;38:426-33.
76. Deugnier YM, Loreal O, Turlin B, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 1992;102:2050-9.
77. Cardoso EM, Hagen K, de Sousa M, Hultcrantz R. Hepatic damage in C282Y homozygotes relates to low numbers of CD8+ cells in the liver lobuli. Eur J Clin Invest. 2001;31:45-53.
78. Porto G, Vicente C, Teixeira MA, et al. Relative impact of HLA phenotype and CD4-CD8 ratios on the clinical expression of hemochromatosis. Hepatology. 1997;25:397-402.
79. Ruddell RG, Knight B, Tirnitz-Parker JE, et al. Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. Hepatology. 2009;49:227-39.
80. Smith PG, Yeoh GC. Chronic iron overload in rats induces oval cells in the liver. Am J Pathol. 1996;149:389-98.
81. Wake K, Sato T. Intralobular heterogeneity of perisinusoidal stellate cells in porcine liver. Cell Tissue Res. 1993;273:227-37.
82. Zou Z, Ekataksin W, Wake K. Zonal and regional differences identified from precision mapping of vitamin a-storing lipid droplets of the hepatic stellate cells in pig liver: a novel concept of addressing the intralobular area of heterogeneity. Hepatology. 1998;27:1098-108.
83. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125-72.
84. Ruddell RG, Oakley F, Hussain Z, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol. 2006;169:861-76.
85. Knittel T, Fellmer P, Muller L, Ramadori G. Bone morphogenetic protein-6 is expressed in nonparenchymal liver cells and upregulated by transforming growth factor-beta 1. Exp Cell Res. 1997;232:263-9.
86. Andriopoulos Jr B, Corradini E, Xia Y, et al. BMP6 Is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482-7.
87. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478-81.
88. Ramm GA, Li SC, Li L, et al. Chronic iron overload causes activation of rat lipocytes in vivo. Am J Physiol. 1995;268:G451-458.
89. Guido M, Rugge M, Leandro G, Fiel IM, Thung SN. Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts. Hepatology. 1997;26:310-4.
90. George DK, Ramm GA, Powell LW, et al. Evidence for altered hepatic matrix degradation in genetic haemochromatosis. Gut. 1998;42:715-20.
91. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJ. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest. 1992;90:282-7.
92. Bridle KR, Crawford DH, Ramm GA. Identification and characterization of the hepatic stellate cell transferrin receptor. Am J Pathol. 2003;162:1661-7.
93. Ramm GA, Britton RS, O'Neill R, Bacon BR. Identification and characterization of a receptor for tissue ferritin on activated rat lipocytes. J Clin Invest. 1994;94:9-15.
94. Benedetti A, Di Sario A, Casini A, et al. Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology. 2001;120:545-56.
95. Gardi C, Arezzini B, Fortino V, Comporti M. Effect of free iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol. 2002;64:1139-45.
96. Montosi G, Garuti C, Martinelli S, Pietrangelo A. Hepatic stellate cells are not subjected to oxidant stress during iron-induced fibrogenesis in rodents. Hepatology. 1998;27:1611-22.
97. Parkes JG, Liu Y, Sirna JB, Templeton DM. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol. 2000;32:233-46.
98. Chen TT, Li L, Chung DH, et al. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med. 2005;202(7):955-65.
99. Li JY, Paragas N, Ned RM, et al. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell. 2009;16:35-46.
100. Todorich B, Zhang X, Slagle-Webb B, Seaman WE, Connor JR. Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem. 2008;107:1495-505.
101. Li L, Fang CJ, Ryan JC, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci USA. 2010;107:3505-10.
102. Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009;49:887-900.
103. Kawada N, Kristensen DB, Asahina K, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem. 2001;276:25318-23.
104. Nakatani K, Okuyama H, Shimahara Y, et al. Cytoglobin/STAP, its unique localization in splanchnic fibroblastlike cells and function in organ fibrogenesis. Lab Invest. 2004;84:91-101.
105. Xu R, Harrison PM, Chen M, et al. Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther. 2006;13:1093-100.
106. Parola M, Pinzani M, Casini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun. 1993;194:1044-50.
107. Svegliati Baroni G, D'Ambrosio L, Ferretti G, et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology. 1998;27:720-6.
108. Tsukamoto H. Oxidative stress, antioxidants, and alcoholic liver fibrogenesis. Alcohol. 1993;10:465-7.
109. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology. 2002;35:62-73.
110. Parkes JG, Templeton DM. Modulation of stellate cell proliferation and gene expression by rat hepatocytes: effect of toxic iron overload. Toxicol Lett. 2003;144:225-33.
111. Olynyk JK, Khan NA, Ramm GA, et al. Aldehydic products of lipid peroxidation do not directly activate rat hepatic stellate cells. J Gastroenterol Hepatol. 2002;17:785-90.
112. Blumberg BS, Lustbader ED, Whitford PL. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci USA. 1981;78:3222-4.
113. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35:635-8.
114. Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937-43.
115. Parkkila S, Niemela O, Britton RS, et al. Vitamin E decreases hepatic levels of aldehyde-derived peroxidation products in rats with iron overload. Am J Physiol. 1996;270:G376-84.
116. Ramey G, Faye A, Durel B, Viollet B, Vaulont S. Iron overload in Hepc1(-/-) mice is not impairing glucose homeostasis. FEBS Lett. 2007;581:1053-7.
117. Gullo L, Corcioni E, Brancati C, et al. Morphologic and functional evaluation of the exocrine pancreas in betathalassemia major. Pancreas. 1993;8:176-80.
118. Lu JP, Hayashi K, Okada S, Awai M. Transferrin receptors and selective iron deposition in pancreatic B cells of iron-overloaded rats. Acta Pathol Jpn. 1991;41:647-52.
119. Kulaksiz H, Fein E, Redecker P, et al. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol. 2008;197:241-9.
120. Minamiyama Y, Takemura S, Kodai S, et al. Iron restriction improves type 2 diabetes mellitus in otsuka long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab. 2010;298:E1140-9.
121. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57:332-9.
122. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans. 2008;36:343-7.
123. Hucl T, Kylanpaa-Back ML, Witt H, et al. HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med. 2007;9:479-83.
124. Ablamunits V, Baranova F, Mandrup-Poulsen T, Nerup J. In vitro inhibition of insulin release by blood mononuclear cells from insulin-dependent diabetic and healthy subjects: synergistic action of IL-1 and TNF. Cell Transplant. 1994;3:55-60.
125. el Nawawy A, Soliman AT, el Azzouni O, et al. Interleukin-1-beta, tumour necrosis factor-alpha, islet-cell antibody, and insulin secretion in children with thalassemia major on long-term blood transfusion. J Trop Pediatr. 1996;42:362-4.
126. Suvarna J, Ingle H, Deshmukh CT. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major. Indian Pediatr. 2006;43:393-400.
127. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr. 2003;162:139-46.
128. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-50.
129. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-14.
130. Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125:1733-41.
131. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S79-86.
132. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am. 2005;89:391-409.
133. Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst. 1985;75:81-4.
134. Fargion S, Mandelli C, Piperno A, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992;15:655-9.
135. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
136. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:491-4.
137. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis. 2002;23:435-45.
138. Knight B, Tirnitz-Parker JE, Olynyk JK. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology. 2008;135:969-79.
139. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112-7.
140. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114-7.
141. Mandishona E, MacPhail AP, Gordeuk VR, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans. Hepatology. 1998;27:1563-6.
142. Brown KE, Mathahs MM, Broadhurst KA, Weydert J. Chronic iron overload stimulates hepatocyte proliferation and cyclin D1 expression in rodent liver. Transl Res. 2006;148:55-62.
143. Chenoufi N, Loreal O, Drenou B, et al. Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J Hepatol. 1997;26:650-8.
144. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 1990;11:566-9.
145. Marrogi AJ, Khan MA, van Gijssel HE, et al. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J Natl Cancer Inst. 2001;93:1652-5.
146. Vautier G, Bomford AB, Portmann BC, et al. p53 Mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology. 1999;117:154-60.
147. Lescoat G, Chantrel-Groussard K, Pasdeloup N, et al. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif. 2007;40:755-67.
148. Bai X, Wu L, Liang T, et al. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:83-91.
149. Jung JO, Gwak GY, Lim YS, Kim CY, Lee HS. Role of hepatic stellate cells in the angiogenesis of hepatoma. Korean J Gastroenterol. 2003;42:142-8.
150. Zindy PJ, L'Helgoualc'h A, Bonnier D, et al. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis. Hepatology. 2006;44:1296-307.
151. Ramm GA, Britton RS, O'Neill R, Kohn HD, Bacon BR. Rat liver ferritin selectively inhibits expression of alpha-smooth muscle actin in cultured rat lipocytes. Am J Physiol. 1996;270:G370-5.
152. Ooi LP, Crawford DH, Gotley DC, et al. Evidence that "myofibroblast-like" cells are the cellular source of capsular collagen in hepatocellular carcinoma. J Hepatol. 1997;26:798-807.
153. Bridle KR, Crawford DH, Powell LW, Ramm GA. Role of myofibroblasts in tumour encapsulation of hepatocellular carcinoma in haemochromatosis. Liver. 2001;21:96-104.
154. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80:1197-213.
155. Porto G, De Sousa M. Iron overload and immunity. World J Gastroenterol. 2007;13:4707-15.
156. Pang YL, Zhang HG, Peng JR, et al. The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother. 2009;58(6):887-86.
157. Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129:428-37.
158. Fabio G, Zarantonello M, Mocellin C, et al. Peripheral lymphocytes and intracellular cytokines in C282Y homozygous hemochromatosis patients. J Hepatol. 2002;37:753-61.
159. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol. 1992;80:235-41.
160. Good MF, Powell LW, Halliday JW. Iron status and cellular immune competence. Blood Rev. 1988;2:43-9.
161. Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci. 1988;526:301-9.
162. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-63.
163. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-4.
164. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-11.
165. Galan P, Noisette N, Estaquio C, et al. Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et mineraux AntioXydants) cohort. Public Health Nutr. 2006;9:70-4.
166. Sempos CT, Looker AC, Gillum RF. Iron and heart disease: the epidemiologic data. Nutr Rev. 1996;54:73-84.
167. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J. 1989;117:1177-88.
168. Meyers DG. The iron hypothesis -does iron cause atherosclerosis? Clin Cardiol. 1996;19:925-9.
169. Ma J, Stampfer MJ. Body iron stores and coronary heart disease. Clin Chem. 2002;48:601-3.
170. Walker AR, Walker BF, Labadarios D. High stored iron and the risk of ischemic heart disease. Circulation. 1993;88:807-8.
171. Higginson J, Gerritsen T, Walker AR. Siderosis in the bantu of southern Africa. Am J Pathol. 1953;29:779-815.
172. Seedat YK, Mayet FG, Khan S, Somers SR, Joubert G. Risk factors for coronary heart disease in the Indians of Durban. S Afr Med J. 1990;78:447-54.
173. Tanguy S, de Leiris J, Besse S, Boucher F. Ageing exacerbates the cardiotoxicity of hydrogen peroxide through the Fenton reaction in rats. Mech Ageing Dev. 2003;124:229-35.
174. Liu XK, Prasad MR, Engelman RM, Jones RM, Das DK. Role of iron on membrane phospholipid breakdown in ischemic-reperfused rat heart. Am J Physiol. 1990;259:H1101-1107.
175. van Jaarsveld H, Potgieter GM, Kuyl JM, Barnard HC, Barnard SP. The effect of desferal on rat heart mitochondrial function, iron content, and xanthine dehydrogenase/oxidase conversion during ischemia-reperfusion. Clin Biochem. 1990;23:509-13.
176. Bar-Or D, McDonald MC, Thiemermann C. Reduction of infarct size in a rat model of regional myocardial ischemia and reperfusion by the synthetic peptide DAHK. Crit Care Med. 2006;34:1955-9.
177. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-5.
178. Thong PS, Selley M, Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol. 1996;42:103-10.
179. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007;232:1014-20.
180. Chevion M, Leibowitz S, Aye NN, et al. Heart protection by ischemic preconditioning: a novel pathway initiated by iron and mediated by ferritin. J Mol Cell Cardiol. 2008;45:839-45.
181. Loncar R, Flesche CW, Deussen A. Myocardial ferritin content is closely related to the degree of ischaemia. Acta Physiol Scand. 2004;180:21-8.
182. Millerot E, Prigent-Tessier AS, Bertrand NM, et al. Serum ferritin in stroke: a marker of increased body iron stores or stroke severity? J Cereb Blood Flow Metab. 2005;25:1386-93.
183. Lee SD, Huang CY, Shu WT, et al. Pro-inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta. 2006;370:50-6.
184. Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987;76:906-15.
185. Ramu E, Korach A, Houminer E, et al. Dexrazoxane prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart. Cardiovasc Drugs Ther. 2006;20:343-8.
186. Chekanov VS, Nikolaychik V, Maternowski MA, et al. Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. Ann Thorac Surg. 2003;75:184-9.
187. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and ironoverload cardiomyopathy. J Mol Med. 2006;84:349-64.
188. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-94.
189. Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci. 2003;10:510-7.
190. Minqin R, Rajendran R, Pan N, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med. 2005;38:1206-11.
191. Campbell S, George DK, Robb SD, et al. The prevalence of haemochromatosis gene mutations in the west of Scotland and their relation to ischaemic heart disease. Heart. 2003;89:1023-6.
192. Pankow JS, Boerwinkle E, Adams PC, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the atherosclerosis risk in communities (ARIC) study. Transl Res. 2008;152:3-10.
193. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002;113:472-9.
194. Turoczi T, Jun L, Cordis G, et al. HFE mutation and dietary iron content interact to increase ischemia/reperfusion injury of the heart in mice. Circ Res. 2003;92:1240-6.